European Neurologists’ Opinions on Alzheimer’s Disease

Alzheimer's disease (AD) remains a critical area in healthcare research, demanding timely diagnosis and advanced care options. A new survey among European neurologists underscores the imperatives of early detection, the significance of primary care gateways, and the essential role of innovation in transforming AD management.

Key findings include:

• 83% of surveyed neurologists believe that pharmaceutical innovation will have a significant positive impact on Alzheimer's disease patients and their families
• 87% of surveyed neurologists agree that diagnosing AD early during Mild Cognitive Impairment (MCI) or Mild Dementia stages offers patients significantly better care options
• 97% of neurologists surveyed report that patients or their families often attempt to hide or downplay dementia symptoms during initial consultations
• PCPs are recognised by 75% of neurologists as playing a critical role in detecting and referring patients with memory complaints. However, 53% of surveyed neurologists consider PCPs not knowledgeable enough about AD

Technical note
On behalf of Eli Lilly and Company, Ipsos UK conducted an online survey among 400 neurologists across four countries (France, Italy, Spain, Germany; n=100 in each country) between 4th July and 30th July 2025. All voluntarily chose to participate. All respondents had been medically qualified for 3-30 years, spent the majority of their clinical time in a hospital setting, spent at least 60% of their professional time in direct patient care, and were actively treating patients with AD. The overall total results are based on a global average across the four countries, and data was weighted equally across the surveyed countries.